Highlights
Current estimates of the global burden of AMR are limited by lack of data.
Choice of methodological approach for calculating AMR burden impacts on estimates.
Patient-focussed surveillance of drug-resistant infection is a priority.
International collaboration to build sustainable AMR surveillance is essential.